title: Reply to 'Rituximab activity in CD20-positive multiple myeloma'.
authors.forename: A
authors.initials: A
authors.lastname: Gozzetti
authors.forename: A
authors.initials: A
authors.lastname: Fabbri
authors.forename: S
authors.initials: S
authors.lastname: Lazzi
authors.forename: M
authors.initials: M
authors.lastname: Bocchia
authors.forename: F
authors.initials: F
authors.lastname: Lauria
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D012074:Remission Induction; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000069283:Rituximab